/ 3A5 in human liver S9 and hepatocytes. We synthesized the proposed compounds 2–4 and determined the metabolite structure by LC-MS/MS analysis. Metabolites 2–4 were synthesized by rearrangement of isoquinoline N-oxide and/or by using (S)-5-keto-2-methyl-1,4-diazepane moiety as a key structure, which in turn was prepared from (R)-3-amino-2-propanol and 3-amino-propionic acid through a Mitsunobu intramolecular
在人体中, ( S )-4-fluoro-5-(2-methyl-1,4-diazepan-1-ylsulfonyl)-isoquinoline hydrochloride dihydrate (K-115, 1 ) 的氧化代谢物2 – 4,一种新型 Rho-激酶
抑制剂,主要由人肝脏 S9 和肝细胞中的醛氧化酶和 CYP3A4 / 3A5 形成。我们合成了建议的化合物2-4,并通过 LC- MS /MS 分析确定了代谢物结构。代谢物2-4是通过
异喹啉N-氧化物的重排和/或使用 ( S )-5-keto-2-methyl - 1,4 -diazepane 部分作为关键结构合成的,而后者又由 ( R)-3-
氨基-2-
丙醇和3-
氨基-
丙酸通过Mitsunobu分子内环化反应。